GlaxoSmithKline plc has announced the successful completion of the tender offer by its wholly-owned subsidiary Gemstone Acquisition Corporation for shares of common stock of Genelabs Technologies, Inc. The tender offer expired at 12:00 midnight, New York City time, on Tuesday, January 6, 2009. The depositary for the tender offer has advised GSK that shareholders
Full Post: GSK completes tender offer for shares of Genelabs Technologies
When an obesity drug called Leptin was first discovered by scientists 13 years ago, experts hoped the appetite-suppressing hormone would be a possible cure for obesity.
Leptin failed to realise those expectations and it was discovered that overweight people became unresponsive to Leptin very quickly due to the development of resistance in the brain but scientists at Harvard University have now found a way to stop the brain blocking its influence.
They have discovered that the substances Buphenyl (4-PBA) and Tauroursodeoxycholic acid (TUDCA) stop the brain from ignoring Leptin and the drug is once again being considered as a way to deal with the escalating levels of obesity.
Dr. Umut Ozcan, who led the study, says most humans who are obese have Leptin resistance and researchers have been searching for years for a drug to make peoples’ brains sensitive to Leptin again.
Leptin works by diminishing the amount of pleasure received from food and after treatment overweight patients find their hunger reduced, they became more particular about food and they lose weight. However, the brain quickly gets used to the hormone, builds up a resistance and Leptin loses its affect.
Both 4-PBA and TUDCA are available over the counter as treatments for cystic fibrosis and liver disease and are available in pill form and in experiments with mice Dr. Ozcan found that pre-treating them with 4-PBA or TUDCA, Leptin sensitivity was boosted and the mice had significant weight loss even when fed a high-fat diet.
Dr. Ozcan says the study provides evidence that chemical chaperones, particularly the PBA and TUDCA, can be used as leptin-sensitizing agents and as all have a high safety record, they could together present a new treatment option for obesity.
The study is published in the current issue of Cell Metabolism.
--------------------------------------------------------------------------------------------
Related Posts:
A new study in the January 7th issue of Cell Metabolism, a Cell Press publication, helps to explain why obese people and animals fail to respond to leptin, a hormone produced by fat that signals the brain to stop eating. What’s more, they show that two FDA-approved drugs might restore leptin sensitivity, offering a novel
Full Post: Novel treatment option for obesity
The discovery more than a decade ago of leptin, an appetite-suppressing hormone secreted by fat tissue, generated headlines and great hopes for an effective treatment for obesity. But hopes dimmed when it was found that obese people are unresponsive to leptin due to development of leptin resistance in the brain. Now, researchers at Children’s Hospital
Full Post: New hope for leptin as a solution to obesity
Patients with the skin disease psoriasis appear more likely to have higher levels of leptin (a hormone produced by fat cells that may contribute to obesity and other metabolic abnormalities) than persons without psoriasis, according to a report in the December issue of Archives of Dermatology. Psoriasis is an autoimmune disease that results in a
Full Post: Psoriasis sufferers more likely to have higher levels of leptin
Obese people who don’t have high cholesterol or diabetes might think they’re healthy - despite the extra pounds. But new Ohio University research suggests that obesity raises levels of the hormone leptin, which can be as big a threat to the cardiovascular system as cholesterol. Tadeusz Malinski and colleagues have published the first study to directly
Full Post: Obesity raises levels of hormone leptin
A new mathematical model of the physiological regulation of body weight suggests a potential mechanism underlying the difficulty of losing weight, one that includes aspects of two competing hypotheses of weight regulation. In the January issue of Cell Metabolism, Massachusetts General Hospital (MGH) investigators outline a system in which there may be several steady states
Full Post: New model system may better explain regulation of body weight --------------------------------------------------------------------------------------------
